Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant
Pilot Study of Leflunomide as First Line Therapy for Musculoskeletal GVHD
Graft versus host disease (GVHD) is a well-known complication of allogeneic transplant. In GVHD, the cells of the donor attack the patient's tissues and cause damage. It can affect any organ or system of the body. In a proportion of patients, it affects the joints and muscles. This is known as musculoskeletal GVHD. The standard treatment of musculoskeletal GVHD is steroids. However, these are usually needed for prolonged periods, and cause a large number of additional problems in transplant patients.
Leflunomide is a drug which has been used for several years in diseases like rheumatoid arthritis (RA). RA is an auto-immune disorder. The biological mechanisms underlying RA and musculoskeletal GVHD are quite similar. Hence it is likely that leflunomide may work in musculoskeletal GVHD also. The investigator have previously used leflunomide in a few patients with musculoskeletal GVHD and have found it to be extremely effective. Also, it was very safe (unlike steroids). Yet another advantage is that it is fairly cheap.
The purpose of the current study is to study the efficacy and safety of leflunomide in patients with musculoskeletal GVHD in a prospective way.
연구 개요
상세 설명
The curative potential of allogeneic hematopoietic stem cell transplantation (allo-HCT) is hampered by acute and chronic graft-versus-host disease (GVHD). Although chronic GVHD (cGVHD) can affect any organ / system in the body, commonly affected are skin, oral cavity, eyes, liver, joints and fascia, and lungs. Involvement of these can occur alone or concurrently, and these lead to a significant negative impact on the patient's quality of life. Musculoskeletal involvement in chronic GVHD (mGVHD) can have varied presentations like fasciitis, myositis, arthritis, etc. The basic pathogenesis of mGvHD closely mimics autoimmune disorders like rheumatoid arthritis, systemic sclerosis, systemic lupus, etc.
The treatment goals of mGvHD include improvement or stabilisation of manifestations, limitation of long-term treatment related toxicities, improvement in functional capacity and quality of life. Corticosteroids, the standard frontline treatment, are typically administered for a median of 2 to 3years, leading to substantial morbidity. An effort to decrease corticosteroid doses has led to their use in combination with other drugs, such as cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, rituximab, etanercept, ruxolotinib, imatinib, ibrutinib, ECP (extra corporeal photopheresis), methotrexate etc, in frontline or second-line settings. All these drugs have been used with far and few responses but with significant treatment related toxicity and costs. As far as musculoskeletal GVHD is concerned, the British guidelines recommend corticosteroids as first line treatment and rituximab as second line option. However, the morbidity associated with long term steroid use warrants a quest for use of non-steroid therapies to be used in 1st line setting for chronic GVHD.
Leflunomide has been used in rheumatoid arthritis. At our centre, the investigator have previously used leflunomide for patients with musculoskeletal GVHD and found it to be effective and safe. Leflunomide is relatively cheap and potentially more effective compared to other more expensive alternatives. If proven to be effective in a larger cohort of patients, this drug could become the standard first line agent in this setting.
With this, the investigator have planned to carry out this study to assess the efficacy of leflunomide in musculoskeletal GVHD post allogeneic stem cell transplant.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Sachin Punatar, MD, DM
- 전화번호: 5096 02227405000
- 이메일: drsachin_punatar@yahoo.in
연구 장소
-
-
Maharashtra
-
Navi Mumbai, Maharashtra, 인도, 410210
- 모병
- Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer
-
연락하다:
- Sachin Punatar, DM
- 전화번호: 5096 022-24705000
- 이메일: drsachin_punatar@yahoo.in
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Willing to give written informed consent
- Patients diagnosed with musculoskeletal mGvHD based on 2014 NIH consensus criteria (with diagnosis confirmed by biopsy only if clinically required).
- Willing and able to comply with all study requirements, including treatment, and periodic assessments.
Exclusion Criteria:
- Patients with known hypersensitivity to leflunomide especially previous Steven Johnson syndrome, toxic epidermal necrolysis after leflunomide.
- Pregnant females
- Patients with musculoskeletal manifestations explained by other potential causes ( (drugs, trauma, etc).
- Patients with calculated glomerular filtration rate (GFR) <30ml/min at the time of screening.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Leflunomide Arm
Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.
This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
|
Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. The dosing for children will be as follows:
This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall objective response rate
기간: Through study completion, an average of 2 years
|
Response will be defined as per the NIH 2014 consensus response criteria working group for mGvHD.
|
Through study completion, an average of 2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to response
기간: From date of start of leflunomide to date of first documented response, assessed up to 2 Years
|
The time required to achieve complete or partial response after treatment.
|
From date of start of leflunomide to date of first documented response, assessed up to 2 Years
|
|
Time to best response
기간: From date of start of leflunomide to date of documented best response, assessed up to 2 Years
|
Time to best response will be recorded.
|
From date of start of leflunomide to date of documented best response, assessed up to 2 Years
|
|
Duration of response
기간: From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
|
The duration of response will be calculated from the time of onset of objective response after initiation of treatment with leflunomide until the end of the follow-up, GVHD relapse, the development of new or the deterioration of pre-existing mGVHD symptoms, or the reinstitution of any additional agents to control the disease.
|
From date of first documented response to date of first documented progression or relapse, assessed up to 2 years
|
|
Relapse rate
기간: Through study completion, an average of 2 years
|
Relapse rate of mGVHD after stopping leflunomide will be recorded.
|
Through study completion, an average of 2 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sachin Punatar, MD, DM, Tata Memorial Centre
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 900643
- CTRI/2021/04/033214 (레지스트리 식별자: Clinical Trials Registry- India (CTRI))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Leflunomide tablet에 대한 임상 시험
-
University Hospital, Clermont-FerrandDr Gisèle PICKERING (MCU-PH)(Clinical Pharmacology center, Inserm 501); Dr Gilles DUCHEIX...완전한
-
Hevert-Arzneimittel GmbH & Co. KG완전한
-
Advancis Pharmaceutical Corporation완전한
-
University of Maryland, BaltimoreNational Center for Advancing Translational Sciences (NCATS); University of Maryland Baltimore...완전한
-
Temple UniversityVeloxis Pharmaceuticals완전한
-
VITATOPSNational Health and Medical Research Council, Australia; National Heart Foundation, Australia 그리고 다른 협력자들완전한뇌졸중 | 일시적 허혈 발작홍콩, 영국, 네덜란드, 싱가포르, 호주, 뉴질랜드, 이탈리아, 인도, 말레이시아, 포르투갈, 미국, 스리랑카, 필리핀 제도, 오스트리아, 벨기에, 브라질, 그루지야, 몰도바 공화국, 파키스탄, 세르비아
-
Oswaldo Cruz FoundationConselho Nacional de Desenvolvimento Científico e Tecnológico모병